None listed
Conditions
Brief summary
Obesity is a major public and personal global health issue. A major clinical issue in managing the obese individual is the prevention of weight regain following successful weight loss initiatives. There has been recent interest in the role of the central neurotransmitter dopamine on appetite control and energy balance, and several small studies have suggested that dopamine agonist medication could be a novel way to treat obesity. This randomised controlled trial will identify if the dopamine agonist drug Cabergoline is effective at preventing weight regain. 200 obese people will be included in the trial and followed for 2 years. A subset of these participants will complete additional procedures to measure brain activity changes alongside weight loss and study medication. If Cabergoline is successful at preventing weight regain it could have a major impact on how obesity is managed and could open up an new area of future research for this class of medication
Interventions
Cabergoline 0.5mg once weekly taken orally for two years
Sponsors
Health Research Council
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
20 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
BMI>30 (lean participants for substudy - BMI <25) Male or female 20-65 years pre-menopausal women must be using apropriate contraception
Exclusion criteria
BMI <30 (lean participants for substudy - BMI >25) Diabetes Malignance Cardiac disease vascular disease uncontrolled hypertension psychiatric disease other significant medical condition women with child-bearing potential (not on appropriate contraception) Participants using medication that could interact with cabergoline
Outcome results
None listed